Linaclotide: first global approval.

Article Details

Citation
Copy to clipboard

McWilliams V, Whiteside G, McKeage K

Linaclotide: first global approval.

Drugs. 2012 Nov 12;72(16):2167-75. doi: 10.2165/11470590-000000000-00000.

PubMed ID
23083112 [ View in PubMed
]
Abstract

Linaclotide is a once-daily, orally administered, first-in-class agonist of guanylate cyclase-C that is minimally absorbed. It is being developed to treat gastrointestinal disorders by Ironwood Pharmaceuticals and its partners, Forest Laboratories (North America), Almirall (Europe) and Astellas Pharma (Asia-Pacific). Linaclotide has received its first global approval in the US for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC), and a marketing submission has been filed in the EU for IBS-C. This article summarizes the milestones in the development of linaclotide leading to this first approval for IBS-C and CIC. This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

DrugBank Data that Cites this Article

Drugs